General Information of the Drug (ID: M6APDG02706)
Name
GW1929
Synonyms
GW 1929; GW-1929
    Click to Show/Hide
Status
Investigative
Structure
Formula
C30H29N3O4
InChI
1S/C30H29N3O4/c1-33(28-13-7-8-18-31-28)19-20-37-24-16-14-22(15-17-24)21-27(30(35)36)32-26-12-6-5-11-25(26)29(34)23-9-3-2-4-10-23/h2-18,27,32H,19-21H2,1H3,(H,35,36)/t27-/m0/s1
InChIKey
QTQMRBZOBKYXCG-MHZLTWQESA-N
PubChem CID
6518171
TTD Drug ID
D04DYM
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Peroxisome proliferator-activated receptor gamma (PPAR-gamma)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
Response Summary Peroxisome proliferator-activated receptor gamma (PPAR-gamma) is a therapeutic target for GW1929. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of GW1929 through regulating the expression of Peroxisome proliferator-activated receptor gamma (PPAR-gamma). [1], [2]
References
Ref 1 The m(6)A demethylase FTO promotes the osteogenesis of mesenchymal stem cells by downregulating PPARG. Acta Pharmacol Sin. 2022 May;43(5):1311-1323. doi: 10.1038/s41401-021-00756-8. Epub 2021 Aug 30.
Ref 2 T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem. 2002 May 31;277(22):19649-57. doi: 10.1074/jbc.M200743200. Epub 2002 Mar 4.